ArriVent BioPharma, Inc. (AVBP) AI Stock Analysis

• Market Cap: $980.39M
• Dividend Yield: N/A
• Average Volume (3M): 516.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: N/A
• EPS Growth: -75.31%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.84
• Shares Outstanding: 44,201,622
• 10 Day Avg. Volume: 629,954
• 30 Day Avg. Volume: 516,005
• PEG Ratio: -0.07
• Price to Book (P/B): 2.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.82
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.38
• 1Y Price Target: $43.22
• Price Target Upside: 94.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -3.77
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $24.50 ▲(10.46% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is mainly constrained by weak financial performance driven by no revenue and accelerating losses/cash burn, partially offset by a low-leverage, well-capitalized balance sheet. Technicals are moderately constructive with price above major moving averages and neutral momentum. Valuation remains pressured due to losses (negative P/E), while the recent positive AACR pipeline update provides a modest support.

Positive Factors

Low leverage / strong balance sheet

Near-zero debt and a materially larger equity base provide durable financial flexibility for a clinical-stage biotech. This reduces refinancing risk, supports multi-phase trial funding, and allows strategic partnering or program prioritization without immediate dependence on dilutive financing.

Negative Factors

Pre-commercial / no revenue

Being pre-revenue is a structural constraint: operations rely entirely on financing or partnerships rather than product cash flow. Long-term sustainability depends on clinical success and timely funding, making the business vulnerable to trial setbacks and capital market cycles over the next several months.

ArriVent BioPharma, Inc. Business Overview & Revenue Model

Company Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the develo...

Read more

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the develo...

How the Company Makes Money

null...

ArriVent BioPharma, Inc. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-177.53M	-80.49M	-74.59M	0.00	-51.61M
Net Income	-166.31M	-80.49M	-69.33M	-36.91M	-51.61M
Balance Sheet
Total Assets	333.17M	274.94M	163.10M	182.83M	43.04M
Cash, Cash Equivalents and Short-Term Investments	312.82M	218.86M	150.39M	163.37M	37.28M
Total Debt	14.00K	176.00K	317.00K	139.00K	0.00
Total Liabilities	25.95M	17.29M	11.80M	8.37M	1.82M
Stockholders Equity	307.22M	257.65M	151.30M	174.46M	41.22M
Cash Flow
Free Cash Flow	-160.59M	-70.21M	-55.84M	-43.63M	-12.59M
Operating Cash Flow	-160.59M	-70.21M	-55.84M	-43.63M	-12.59M
Investing Cash Flow	-71.23M	-192.47M	0.00	0.00	-40.00M
Financing Cash Flow	203.06M	186.58M	42.86M	169.72M	89.87M

ArriVent BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 22.18
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Neutral. The current price of 22.18 is below the 20-day moving average (MA) of 23.80, below the 50-day MA of 22.94, and above the 200-day MA of 21.19, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 42.63 is Neutral, neither overbought nor oversold. The STOCH value of 8.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AVBP.

ArriVent BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IOVA	62 Neutral	$1.50B	-2.50	-54.54%	―	175.62%	19.63%
RLAY	59 Neutral	$1.76B	-5.25	-43.17%	―	-16.50%	33.02%
AVBP	55 Neutral	$980.39M	―	-62.48%	―	―	-75.31%
TSHA	55 Neutral	$1.30B	-16.13	-56.64%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVA	47 Neutral	$1.26B	-0.42	536.36%	―	-12.52%	-82.84%
QURE	45 Neutral	$935.15M	-6.92	-174.03%	―	-44.90%	11.49%

ArriVent BioPharma, Inc. Corporate Events